Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
In a year marked by significant volatility, 3Pea International Inc. (PAYS) stock has recorded a new 52-week low, dipping to $1.95. According to InvestingPro data, despite the company’s strong revenue growth of 23.5% and analysts setting price targets between $5-$7.25, the stock continues to face pressure. This latest price level reflects a stark contrast to the stock’s performance over the past year, with PAYS experiencing a substantial decline of 54.66% in its year-over-year change. Investors have been closely monitoring the company’s trajectory as it navigates through a challenging economic landscape, which has seen many stocks grappling with similar downward pressures. The 52-week low serves as a critical indicator for shareholders and potential investors, signaling a period of reassessment and potential strategy shifts for 3Pea International Inc. as it looks to regain its footing in the market. With current trading levels below InvestingPro’s Fair Value assessment, investors seeking detailed analysis can access the comprehensive Pro Research Report, available exclusively with an InvestingPro subscription.
In other recent news, Paysign Inc. reported its fourth-quarter earnings for 2024, which slightly exceeded expectations with revenue reaching $15.61 million compared to the forecasted $15.45 million. The company’s full-year revenue increased by 23.5% to $58.4 million, driven by strong performance in its plasma and patient affordability segments. Adjusted EBITDA for the year also saw a significant rise of 43.3%, highlighting improved operational efficiency. Paysign’s management has projected 2025 revenue to be between $68.5 million and $70 million, indicating anticipated growth of 17.5% to 20%.
Additionally, the company announced the acquisition of Gamma Innovation LLC, positioning itself for expansion in the SaaS market. This acquisition aims to enhance Paysign’s capabilities in both the plasma and pharmaceutical industries. Analyst firm DA Davidson maintained its Buy rating for Paysign, with a steady price target of $6.00, following the company’s positive earnings report. The firm’s analyst mentioned plans to update forecasts based on the new information provided by Paysign’s management. These developments suggest a promising outlook for Paysign as it enters the next fiscal year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.